Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Aligos Therapeutics. The associated price target remains the same with $50.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Trucchio’s rating is based on Aligos Therapeutics’ significant progress in its drug development pipeline, particularly with its promising treatments for chronic hepatitis B virus (HBV) and metabolic dysfunction-associated steatohepatitis (MASH). The company’s next-generation capsid assembly modulator, ALG-000184, has shown durable viral suppression and multi-antigen reductions, positioning it as a potential monotherapy with a clear path to regulatory approval. This progress is supported by the ongoing Phase 2 B-SUPREME trial, which aims to demonstrate superiority over existing treatments and further solidify ALG-000184’s role as a backbone for functional-cure combinations.
Additionally, Aligos’ ALG-055009, a thyroid hormone receptor-beta agonist, has demonstrated significant liver fat reduction and favorable lipid effects without the side effects seen in earlier treatments. The potential for collaboration and non-dilutive funding in 2026 could accelerate its development, adding to the company’s growth prospects. These factors, combined with the large unmet needs these programs address, underpin Trucchio’s Buy rating and the $50 price target for Aligos Therapeutics.